Lantern Pharma Achieves First Complete Response in LP-284 Clinical Trial
Lantern Pharma Inc., a clinical-stage oncology company pioneering the use of AI in cancer drug development, has announced a significant milestone in its Phase 1 clinical trial of LP-284. A heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response—the first complete response observed with LP-284 to date. This promising result underscores the potential of LP-284 in one of the most difficult-to-treat forms of blood cancer and highlights the power of Lantern’s proprietary RADR® AI platform. RADR® accelerates oncology drug development by identifying mechanisms of action, pinpointing biomarker-driven patient subpopulations, and optimizing treatment strategies for clinical use.
Lantern Pharma Achieves First Complete Response in LP-284 Clinical Trial